Replies to post #197248 on Biotech Values

[DewDiligence]

MRK— why would they even advance to further testing?

MRK’s 3-DAA data are tepid, but not awful; from a business standpoint, I don’t think it’s wrong for MRK to advance the 3-DAA regimen to phase-2b. However, I do question whether this regimen is potent enough to support an 8-week duration for all genotypes.